Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Total Current Liabilities (2018 - 2025)

10x Genomics (TXG) has disclosed Total Current Liabilities for 8 consecutive years, with $153.5 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 30.45% to $153.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $153.5 million through Dec 2025, up 30.45% year-over-year, with the annual reading at $153.5 million for FY2025, 30.45% up from the prior year.
  • Total Current Liabilities hit $153.5 million in Q4 2025 for 10x Genomics, up from $147.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $153.5 million in Q4 2025 to a low of $94.4 million in Q1 2022.
  • Historically, Total Current Liabilities has averaged $116.8 million across 5 years, with a median of $112.7 million in 2021.
  • Biggest YoY gain for Total Current Liabilities was 104.09% in 2021; the steepest drop was 31.05% in 2021.
  • Year by year, Total Current Liabilities stood at $110.4 million in 2021, then rose by 18.67% to $131.0 million in 2022, then fell by 2.9% to $127.2 million in 2023, then dropped by 7.49% to $117.6 million in 2024, then soared by 30.45% to $153.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for TXG at $153.5 million in Q4 2025, $147.3 million in Q3 2025, and $112.2 million in Q2 2025.